Are PARP Inhibitors Ready for Prime Time in Metastatic Prostate Cancer? Maybe Not
- 1 January 2024
- journal article
- editorial
- Published by Elsevier BV in European Urology
- Vol. 85 (1), 1-2
- https://doi.org/10.1016/j.eururo.2023.05.017
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) BluesEuropean Urology, 2023
- Rucaparib or Physician’s Choice in Metastatic Prostate CancerThe New England Journal of Medicine, 2023
- Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?European Urology, 2021
- Olaparib for Metastatic Castration-Resistant Prostate CancerThe New England Journal of Medicine, 2020
- When is crossover desirable in cancer drug trials and when is it problematic?Annals of Oncology, 2018
- Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate CancerJournal of Clinical Oncology, 2017
- No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamideExpert Review of Anticancer Therapy, 2014